9/14/2010

FDA staff members will ask an advisory panel whether to withdraw Abbott Laboratories' Meridia because of an increased risk of cardiovascular disease associated with the weight-loss drug. The panel is scheduled to review the treatment Wednesday.

Full Story:
Reuters

Related Summaries